ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2012
Dynamic changes to the endocannabinoid system in models of chronic pain.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 76 citations in OpenAlex.
- Intrathecal morphine administration reduces postoperative pain and peripheral endocannabinoid levels in total knee arthroplasty patients: a randomized clinical trial.BMC anesthesiology · 2018Trial
- Improvement in the Cognitive Function in Chronic Pain: Therapeutic Potential of the Endocannabinoid System.Molecular neurobiology · 2025Review
- The Role of the Insular Cortex and Serotonergic System in the Modulation of Long-Lasting Nociception.Cells · 2024Article
- The New Orientation of Postoperative Analgesia: Remote Ischemic Preconditioning.Journal of pain research · 2024Review
- The Endocannabinoid System and Physical Exercise.International journal of molecular sciences · 2023Review
- Chronic pain, chronic stress and substance use: overlapping mechanisms and implications.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- From a Symptom-Based to a Mechanism-Based Pharmacotherapeutic Treatment in Complex Regional Pain Syndrome.Drugs · 2022Review
- Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.Pharmacological reports : PR · 2021Article
- Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment.Frontiers in physiology · 2021Review
- Review
- Interactions ofFrontiers in pharmacology · 2021Article
- A novel bioassay for quantification of surface Cannabinoid receptor 1 expression.Scientific reports · 2020Article
- Electroacupuncture alleviates morphine‑induced hyperalgesia by regulating spinal CB1 receptors and ERK1/2 activity.Molecular medicine reports · 2019Article
- CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain.Scientific reports · 2019Article
- Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options.Neuronal signaling · 2018Review
- ΔJournal of lipid research · 2018Article
- Contribution of Endocannabinoid Gene Expression and Genotype on Low Back Pain Susceptibility and Chronicity.The Clinical journal of pain · 2018Article
- The cannabinoid system and pain.Neuropharmacology · 2017Review
- Acute Low Back Pain: Differential Somatosensory Function and Gene Expression Compared With Healthy No-Pain Controls.The Clinical journal of pain · 2016Article
- Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice.The Journal of pharmacology and experimental therapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The analgesic effects of cannabinoid ligands, mediated by CB1 receptors are well established. However, the side-effect profile of CB1 receptor ligands has necessitated the search for alternative cannabinoid-based approaches to analgesia. Herein, we review the current literature describing the impact of chronic pain states on the key components of the endocannabinoid receptor system, in terms of regionally restricted changes in receptor expression and levels of key metabolic enzymes that influence the local levels of the endocannabinoids. The evidence that spinal CB2 receptors have a novel role in the modulation of nociceptive processing in models of neuropathic pain, as well as in models of cancer pain and arthritis is discussed. Recent advances in our understanding of the spinal location of the key enzymes that regulate the levels of the endocannabinoid 2-AG are discussed alongside the outcomes of recent studies of the effects of inhibiting the catabolism of 2-AG in models of pain. The complexities of the enzymes capable of metabolizing both anandamide (AEA) and 2-AG have become increasingly apparent. More recently, it has come to light that some of the metabolites of AEA and 2-AG generated by cyclooxygenase-2, lipoxygenases and cytochrome P450 are biologically active and can either exacerbate or inhibit nociceptive signalling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.